SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

V. Novotny-Diermayr, K. Sangthongpitag, C. Y. Hu, X. Wu, N. Sausgruber, P. Yeo, G. Greicius, S. Pettersson, A. L. Liang, Y. K. Loh, Z. Bonday, K. C. Goh, H. Hentze, S. Hart, H. Wang, K. Ethirajulu, J. M. Wood
  • Molecular Cancer Therapeutics, March 2010, American Association for Cancer Research (AACR)
  • DOI: 10.1158/1535-7163.mct-09-0689

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1158/1535-7163.mct-09-0689

The following have contributed to this page: Dr veronica diermayr